Regulation (EU) 2024/1938 on substances of human origin (SoHO) was published in the Official Journal on 17 July 2024 and applies from 7 August 2027, with an extra year for certain provisions. It replaces the separate blood and tissues-and-cells directives with a single, directly applicable regulation. Companies that source human starting materials, including developers of cell and gene therapies and plasma-derived medicines, have less than a year to prepare.
Why a regulation rather than directives
The previous framework, built on Directive 2002/98/EC for blood and Directive 2004/23/EC for tissues and cells, was transposed differently across Member States and struggled with newer practices. The SoHO Regulation creates common EU rules that apply directly. It covers a broader range of substances, including human milk, faecal microbiota and other SoHO, and it strengthens protection for both donors and recipients.
Key features
- SoHO entities: organisations carrying out SoHO activities, such as donor recruitment, collection, testing, processing, storage and distribution, must register. Those performing certain critical activities need authorisation as SoHO establishments.
- SoHO preparations: new or significantly changed preparations require authorisation, with a risk-proportionate approach to clinical outcome monitoring.
- Donor protection: explicit rules on donor eligibility, health monitoring and the voluntary, unpaid donation principle, with clarifications on compensation for losses.
- Governance: a SoHO Coordination Board supports consistent application, and an EU SoHO Platform supports information exchange.
The boundary with medicinal products
Many advanced therapy medicinal products and plasma-derived medicines start with substances of human origin. The SoHO Regulation governs the early steps, such as donation, collection and testing, while the medicinal product framework governs manufacturing and authorisation once the substance becomes a starting material for a medicine. Getting this boundary right matters:
- supply agreements with collection centres and tissue establishments need to reflect the new registration and authorisation status of the supplier
- quality agreements and supplier qualification should map the SoHO requirements onto GMP expectations for starting materials
- borderline products may need classification advice, for which the Regulation provides consultation mechanisms.
A practical readiness checklist
- Inventory every human-derived material in your supply chain and its source.
- Confirm with each supplier its plan for SoHO registration or authorisation.
- Update supplier qualification, audit plans and quality agreements.
- Review donor eligibility and testing documentation against the new requirements.
- Follow implementing acts and national arrangements in Greece and other source countries as they are adopted.
How PQRA helps
PQRA supports companies at the interface between SoHO and medicines legislation. We carry out supply-chain gap assessments, update supplier qualification and quality agreements, and advise on classification questions for products that sit near the boundary.


No responses yet